Thermo Fisher Scientific Opens New Manufacturing Facility in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Thermo Fisher Scientific Opens New Manufacturing Facility in China


ePT--the Electronic Newsletter of Pharmaceutical Technology

Thermo Fisher Scientific has officially opened its new manufacturing facility in Suzhou, China. The company has invested nearly $20 million in the 12,000-m2 (129,167 ft2) plant, which will manufacture life-sciences consumables and equipment as well as establish local production capabilities to meet increasing customer demand in China and other regions in Asia Pacific. The new facility will serve the life-sciences and pharmaceutical industries, including research, diagnostics, and bioproduction, and customers in the chemical, environmental, and electronics industries. More than 150 employees will be housed in this facility and there is room for expansion.

In a press statement, Marc Casper, president and CEO of Thermo Fisher Scientific said, “China is one of our fastest-growing markets and has been a key contributor to our success. The Suzhou facility builds on our well-established presence in China and is an important next step as we closely align our depth of capabilities with China’s five-year plan to develop strategic industries, including pharmaceutical, healthcare, and environmental.”

Thermo Fisher entered the Chinese market 30 years ago and will manufacture plastic labware and consumables in Suzhou, including sample preparation products and filterware, as well as laboratory refrigerators, freezers, incubators, and centrifuges. The new facility will adopt best global and local manufacturing practices, including ISO9001, ISO14001, and ISO13485 standards to ensure an environmentally friendly and safe work environment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here